Myocarditis clinical trials at UCLA
1 research study open to eligible people
open to eligible people ages 18 years and up
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Los Angeles, California and other locations
Our lead scientists for Myocarditis research studies include Eric Yang, MD.